The study evaluates the cost-effectiveness and budget impact of HPV vaccination programs for ten-year-old girls in Kenya as the country transitions from Gavi, the Vaccine Alliance, support. Using a static cohort model, it compares four vaccines (CECOLIN, CERVARIX, GARDASIL-4, and GARDASIL-9) for their cost per DALY averted over 2020-2029. The results show HPV vaccination can significantly reduce cervical cancer cases and deaths, with different vaccines offering varying levels of cost-effectiveness. Substantial government funding will be needed to maintain high coverage rates, and a single-dose strategy may be a cost-saving option.